3M Drug Delivery Systems and GlaxoSmithKline Announce Collaboration to Research and Develop New Formulations of Respiratory Medicines.Business Editors & Health/Medical Writers ST. PAUL St. Paul as a missionary he fearlessly confronts the “perils of waters, of robbers, in the city, in the wilderness.” [N.T.: II Cor. 11:26] See : Bravery , Minn. & LONDON--(BUSINESS WIRE)--Nov. 13, 2001 3M Drug Delivery Systems (DDS (1) (Digital Data Storage) See DAT. (2) (Data Dictionary System) See QuickBuild and OpenDDS. (3) (Dataphone Digital S ) Division and GlaxoSmithKline plc (GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ) today announce that they have initiated a research and development collaboration to formulate novel drugs to fight respiratory diseases, such as asthma and chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. (COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) ). The collaboration will take advantage of GSK's extensive respiratory expertise and range of respiratory products and 3M's novel surfactant Surfactant Definition Surfactant is a complex naturally occurring substance made of six lipids (fats) and four proteins that is produced in the lungs. It can also be manufactured synthetically. technology based on oligolactic acids (OLAs). OLAs are novel excipients excipients, n.pl all the constituents of a remedy that lack medicinal properties. See also adjuvant, auxiliary substance, and vehicle. that increase formulation and performance options for a variety of drugs through increased solubilization or suspendability in metered-dose inhalers (MDIs), the device most commonly used by patients when taking their respiratory medicines. OLAs also have the potential of providing sustained release Sustained-release (SR), extended-release (ER, XR, or XL), time-release or timed-release, controlled-release (CR), or continuous-release (CR or Contin of drugs within the lungs, which may help to develop once-daily formulations. Under the terms of the agreement, 3M will be responsible for initial laboratory testing of certain GSK respiratory compounds, in combination with the 3M OLA Noun 1. ola - leaf or strip from a leaf of the talipot palm used in India for writing paper olla Corypha umbraculifera, talipot, talipot palm - tall palm of southern India and Sri Lanka with gigantic leaves used as umbrellas and fans or cut into strips for inhalation technology. As well as testing new compounds, the collaboration, upon mutual agreement, will also investigate development opportunities with the 3M OLA inhalation technology for currently marketed respiratory products. GSK will be responsible for development and commercialization of those new products identified, and 3M will receive a share of the profits from those new products successfully introduced to the market. "We are pleased to announce this important collaboration agreement with GlaxoSmithKline," said John Sampson, general manager, 3M DDS. "3M DDS's experience with the OLA inhalation technology presents GSK with an entirely new pharmaceutical discovery platform that promises to lead to several exciting new prescription drugs. We are also looking forward to the prospect of continuing this collaboration with GSK as we expand our OLA technology in the future." Garth Rapeport, senior vice president for the Respiratory and Inflammation Centre for Excellence in Drug Discovery, GlaxoSmithKline, said, "Combining the expertise of these two leading respiratory companies is a very exciting prospect. We believe there is real potential to develop several novel respiratory products utilizing 3M's OLA technology, and we look forward to bringing them to patients suffering from respiratory diseases throughout the world." About 3M DDS 3M Drug Delivery Systems Division is a global leader in the development of inhalation and transdermal technologies. As the creator of the first metered-dose inhaler (MDI (1) (Multiple Document Interface) A Windows function that allows an application to display and lets the user work with more than one document at the same time. ), the division has a 45-year history of medical innovation, including introduction of the world's first HFA HFA Harvard Film Archive (Harvard University) HFA Harry Fox Agency, Inc. HFA Housing Finance Agency (District of Columbia government) HFA Hyogo Framework for Action HFA High-Functioning Autism inhalers. Today, 3M DDS components and services are used in over 50 percent of all global MDI devices. Likewise, the company also pioneered the 3M Latitude Transdermal Drug Delivery System, a drug-in-adhesive platform, that can be customized for a variety of therapeutic agents, while delivering medication through a patient's skin for up to a week. Over 80 percent of transdermal systems in the United States contain at least one 3M DDS component. About 3M 3M is a $17 billion technology company with leading positions in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. Headquartered in St. Paul, Minn., the company has operations in more than 60 countries and serves customers in nearly 200 countries. 3M businesses share technologies, manufacturing operations, brands, marketing channels and other important resources. 3M is one of the 30 stocks that make up the Dow Jones Industrial Average Dow Jones Industrial Average The best known U.S. index of stocks. A price-weighted average of 30 actively traded blue-chip stocks, primarily industrials including stocks that trade on the New York Stock Exchange. and also a component of the Standard & Poor's 500 Index. Additional information about the company is available on the Internet (http://www.3M.com). About GlaxoSmithKline GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and health care companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web (www.gsk.com). 3M and Latitude are trademarks of 3M company. GlaxoSmithKline UK media enquiries: Martin Sutton (020) 8966 8000 Philip Thomson (020) 8966 8000 Alan Chandler (020) 8966 8000 European analyst/investor enquiries: Jennie Younger (020) 8966 8378 Duncan Learmouth (020) 8966 5961 Anita Kidgell (020) 8966 8369 GlaxoSmithKline US media inquiries Nancy Pekarek (215) 751-7709 Mary Anne Rhyne (919) 483-2839 US analyst/investor inquiries: Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion